TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS
Compounds according to Formula (I) and Formula (II) are potent inhibitors of PSMA. (I) or (II) Pharmaceutical compositions may include a complex of a radionuclide and a Formula (I) compound or a Formula (II) compound. Methods include using the radionuclide complex of a Formula (I) compound or a Formula (II) compound for treating or diagnosis of a disease or a condition associated with PSMA activity.
-
Paragraph 0245; 0246
(2014/07/23)
More Articles about upstream products of 1620172-28-2